External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ISPOR 2023
Roche and Genentech at

ISPOR 2023

May 07 - May 10
Boston, USA
ispor.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
May 9 / Roche and Genentech
National Trends in Costs and Site of Service of Infused Disease-Modifying Therapies for Multiple Sclerosis
This retrospective study of US commercial claims identified and compared national trends in ocrelizumab▼ and natalizumab costs and site-of-service distribution over time.
Neuroscience Multiple Sclerosis ISPOR-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 8 / Roche and Genentech
Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis
Distributional cost-effectiveness analysis (DCEA) can quantify the potential impact of Alzheimer’s Disease (AD) and its treatment on concerns of health equity. We conducted a literature search to identify studies that investigated the impact of race/ethnicity and social determinants of health on AD outcomes relevant to economic modeling. We identified gaps in the evidence that highlight the need for systematic data collection across equity-relevant subgroups, particularly groups defined by level of social vulnerability. Despite uncertainties, there is sufficient evidence available to evaluate the distributional impact of emerging AD therapies.
Neuroscience Alzheimer Disease ISPOR-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 8 / Roche and Genentech
Machine Learning-Based Explanation of Racial–Ethnic Disparities in 5-Year Cancer-Specific Survival Among Hormone Receptor-Positive Breast Cancer Patients in the United States
This was a retrospective cohort study of patients diagnosed with hormone receptor-positive breast cancer between 2010 and 2016 using data from the Surveillance, Epidemiology, and End Results Program cancer registry and the Centers for Disease Control and Prevention's SocioEconomic Status Index. Concordance of 5-year cancer-specific survival rates predicted by a machine learning model with empirical 5-year cancer-specific survival rates are reported, and drivers of racial disparities in survival between Non-Hispanic White and Non-Hispanic Black patients are characterized.
Oncology Breast Cancer ISPOR-2023

Presented at this congress:

 

Poster:

Increased Real-World Biomarker Test Utilization In Patients With Early-Stage Non-Small Cell Lung Cancer In The United States, 2011 and 2021

Authors: Yan JT, Jin Y, Lo E, Chen Y, Newell A, Kong Y, Inge L

This file is not available.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.